IN8bio Q3 net loss $3.9M ($0.85/share); cash $10.7M; INB-619/100 updates

IN8BIO, INC.

2025-Q3 EPS reported -$4.18

Net loss of $3.9M in Q3 2025 vs $7.1M in Q3 2024; basic and diluted EPS -$0.85 vs -$4.49.
R&D expenses $2.1M (down from $3.3M); G&A $1.9M (down from $2.7M) due to cost-saving measures.
Cash $10.7M as of Sep 30, 2025, up from $4.0M year-over-year.
INB-619 preclinical data at ACR showed B cell elimination similar to blinatumomab/mosunetuzumab with minimal cytokine release.
INB-100 Phase 1 trial expanded to The Ohio State University to accelerate enrollment; updated GBM data planned at SNO Nov 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.